Clinical Trials Logo

Clinical Trial Summary

The investigators hypotheses that paclitaxel combined with cisplatin in a weekly-based regimen as adjuvant chemotherapy is more effective for high risk, HER2 negative breast cancer .

Clinical Trial Description

In this trial, patients will be randomly assigned in a 2:1 ratio to receive cisplatin-based adjuvant chemotherapy and to standard adjuvant chemotherapy. ;

Study Design

Related Conditions & MeSH terms

NCT number NCT03201861
Study type Interventional
Source RenJi Hospital
Contact Yueyao Du, M.D.
Phone 86-21-68385569
Status Recruiting
Phase Phase 3
Start date July 27, 2017
Completion date December 31, 2021

See also
  Status Clinical Trial Phase
Recruiting NCT02221999 - Weekly Paclitaxel and Cisplatin to Treat Hormone Receptor Positive and Triple Negative Breast Cancer Patients Phase 2/Phase 3
Recruiting NCT02879513 - Trial of Adjuvant Chemotherapy in Breast Cancer Patients With Pathological Partial Response and Complete Response to Neoadjuvant Chemotherapy Phase 3
Completed NCT02199418 - Addition of Cisplatin to Neoadjuvant Therapy for T Locally Advanced Breast Cancer Phase 2